
In the 12-month phase 3 zzso study, zzso showed greater efficacy than intramuscular zzso beta zzso in patients with zzso multiple sclerosis zzso This study analyzed zzso efficacy compared with zzso in patient zzso from zzso Patients were zzso to receive zzso or weekly IM zzso for 12 zzso zzso of efficacy included annualized zzso rate zzso and magnetic resonance imaging zzso measures zzso zzso zzso zzso zzso enlarged zzso zzso zzso brain volume zzso zzso were defined based on zzso disease characteristics zzso zzso score, zzso rate, and zzso zzso and response to previous zzso zzso zzso zzso reduced zzso over 12 months by zzso % relative to zzso in all zzso defined by demographic factors or baseline disease zzso zzso also reduced the number of new zzso zzso active zzso zzso and the rate of brain volume loss, versus zzso in most (95 zzso zzso In patients with high disease activity despite zzso treatment in the year before study, zzso zzso zzso reduced zzso by 61 % relative to zzso zzso in zzso counts and brain volume loss also favored zzso in these zzso In conclusion, consistently better efficacy was observed for zzso compared with zzso across different zzso of patients with zzso 

